| Ticker Symbol: | DVAX |
|---|---|
| Exchange: | NASD |
| Contact Info: | 2929 Seventh Street Berkeley CA 94710-2753 510 848-5100 |
| CEO/President: | Dino Dina M.D. |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax\'s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. |
| Shares Outstanding: | 39,810 (000) | Market Value: | 10,350 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 62.31% | Number of Inst.Shareholders: | 5.80% |
| Last Quarter Sales: | 8.86 ($Mil.) | Last Quarter Net Income: | -5.42 ($Mil.) |
| Last Quarter EPS: | -0.14 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.90 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
